growth disorders
DESCRIPTION
Growth Disorders. Most children evaluated for short stature are normal stature variants . The slow growth patterns of these children reflect familial short stature and/or constitutional delay of growth and puberty. Familial short stature. Tend to be small at birth - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/1.jpg)
Growth Disorders
![Page 2: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/2.jpg)
• Most children evaluated for short stature are normal stature variants.
• The slow growth patterns of these children reflect familial short stature and/or constitutional delay of growth and puberty
![Page 3: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/3.jpg)
![Page 4: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/4.jpg)
![Page 5: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/5.jpg)
![Page 6: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/6.jpg)
![Page 7: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/7.jpg)
Familial short stature
• Tend to be small at birth• They grow approximately parallel to the
normal curve but below the 3rd percentile from infancy
• Pubertal development and the acceleration of growth occur normally and they ultimately achieve a short adult height(Father <163 cm,Mother <150 cm)
![Page 8: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/8.jpg)
• They have no clinical or laboratory evidence of endocrine or systemic disease
• Their annual growth rates are within normal limits
• The bone age is appropriate for his or her chronological age
![Page 9: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/9.jpg)
![Page 10: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/10.jpg)
• The diagnosis of familial short stature has been perpetuated in families in which impaired growth was eventually proved to be consequence of a defined genetic disorder.
![Page 11: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/11.jpg)
Constitutional delay in growth and puberty(CDGP)
• They mature at a slower than normal rate• Height and bone age are usually delayed by 2-4
years• Onset of pubertal maturation is understandably
delayed appropriate to the child’s bone age• Often there is a history of delay in growth and
pubertal development of either parent or another relative
• Final adult stature, which may not be reached until the age of 20 or more years, is appropriate for parental target height range
![Page 12: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/12.jpg)
• They are usually of normal size at birth• They grow normally for several months or years but then
deviate from the “normal” growth centiles, particularly in the pre/peri-pubertal years
• They grow at a normal rate for their bone age• There is a later than average adolescent “growth spurt”• Treatment: controversial• Synthetic steroids designed to have an increased
anabolic-androgenic ratio:oxandrolone(oral)(hepatotoxic-hepatic tumors!)
• No suitable equivalent for the girl
![Page 13: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/13.jpg)
![Page 14: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/14.jpg)
A child’s current centile must be evaluated in terms of:
• Genetic background• Gestational or past medical history• Environment• Physical findings• Growth pattern since birth• Current growth rate(height velocity)
![Page 15: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/15.jpg)
Causes of short stature 1- Familial or congenital conditions• Skeletal dysplasias• Chromosomal abnormalities• Forms of intrauterine growth retardation which may
result in show or abnormal growth throughout later life 2- Chronic systemic disorders:• (Due to) insufficient intake of energy and/or protein-
nutritional insufficiency, malabsorption syndromes and chronic inflammatory bowel disease)
• Insufficient oxygenation of tissues• Electrolyte imbalance(chronic renal failure)
![Page 16: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/16.jpg)
3-Endocrine abnormalities• CNS or hypothalamic abnormalities which
affect regulation of the anterior pituitary• Anterior pituitary disorders, either
developmental or acquired which can affect synthesis or secretion of growth hormone or the trophic hormones(TSH,LH,FSH,ACTH)
• Primary dysfunction of the target organs e.g. Thyroid,adrenal or gonadal disease
![Page 17: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/17.jpg)
• Peripheral target tissue abnormalities- a diminished or absent hormone receptor or tissue
enzyme defect Laron type “dwarfism” – failure of IGF1 generation in
response to GH (A GH receptor defect)
- Disorders related to the interaction of the IGF’s or other related peripheral growth factors with chondrocytes and mucopolysaccharides in epiphyseal growth cartilage
Pygmies:genetic defect in IGF-1 responsiveness associated with diminished IGF-1 binding
![Page 18: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/18.jpg)
![Page 19: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/19.jpg)
![Page 20: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/20.jpg)
Normal human growth hormone secretion
• In the first days of life, very high levels of GH occur. After 2 weeks of age, lower mean levels are found.
• In pubertal children, the basal plasma GH concentration is not significantly different from that reported for adults but more peaks of GH may occur during the day with greater amplitude of GH peaks during the night
• The most consistent period of GH secretion for both children and adults occurs within one hour or so after the onset of sleep.The initial surge of GH secretion often correlates with the onset of stage 3 or 4 (slow wave) sleep
![Page 21: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/21.jpg)
Control of human growth hormone secretion
• Positive releasing factor GHRH-Ghrelin• Inhibitory factor:GHRIH• Naturally occurring events that trigger GH
secretion in man are exercise, physical and emotional stresses and high protein intake
![Page 22: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/22.jpg)
Normal regulation of GH• The neurone system regulating GHRH and
GHRH release receives a variety of normal impulses.Impulses arising in the hippocampus are stimulatory whereas those arising in the amygdaloid nuclei can be either stimulatory or inhibitory. The inhibitory inputs are presumed to activate GHRIH release via the anterior somatostinergic pathways,the stimulatory pathway is by way of the ventromedial(VM) nucleus of the hypotalamus
![Page 23: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/23.jpg)
• The GH regulatory neurone system also recieves impulses from each of the ascending monoaminergic neuronal systems :
dopaminergic, noradrenergic and serotonergic - L-Dopa(converted to dopamine) in the brain
leads to a release of GH - Sleep induced GH release is predominantly
mediated by serotonergic fibres. - Hypoglycemia induced GH release is mediated
by noradrenergic pathways.
![Page 24: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/24.jpg)
GH provocation tests• Exercise• Sleep • Arginine infusion• Glucagon• Clonidine (alfa adrenergic receptor stimulant)• ITT• L-Dopa• Priming(sex hormones)??
![Page 25: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/25.jpg)
Physiologic effects of human growth hormone
• Anabolic-promotes protein synthesis in muscle cells
• Catabolic effect- on fat and carbonhydrate metabolism (short term hypoglycemic effect) inducing lipolysis in adipoctytes
• Long term effect of high GH levels:plasma glucose concentration increases(increased glucose production and reduced glucose utilization)
![Page 26: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/26.jpg)
Evalution of height measurements
1- Growth charts2- Parental heights- target height3- Height SDS4- Height velocity5- Predicted ht SDS:X-x* SDx*:mean height for age and gender
![Page 27: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/27.jpg)
Etiology and pathogenesis of growth failure
• Chromosomal assessment Turner Sydrome• FSS• IUGR “Catch up”• CDGP• Skeletal dysplasia
osteochondrodysplasias(achondroplasia, hypochondroplasia)
![Page 28: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/28.jpg)
• Chronic systemic disorders- asthma• Nutritional insufficiency• Chronic gastrointestinal diseases Coeliac disease Crohn’s disease Ulcerative colitis• Chronic renal disease• Cardiac disease• DM
![Page 29: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/29.jpg)
Endocrine abnormalities• Primary hypothyrodism• Gonadal dysgenesis• GHD• Glucocorticoid excess• Growth failure to pyschosocial deprivation
![Page 30: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/30.jpg)
Etiology of GHD
• Congenital Acquired
• İsolated MPHD
![Page 31: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/31.jpg)
![Page 32: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/32.jpg)
![Page 33: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/33.jpg)
• Incidence 1/4000-10000 live births• (50-60%) idiopathic • Hereditary (aut.recessive or dominant)
![Page 34: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/34.jpg)
Developmental defects
• Pituitary aplasia-hypoplasia • Midline abnormalities - Severe holoprosencephaly septooptic
dysplasia (SOD):Hypoplasia of the optic nerves dysgenesis or agenesis of the infundibulum and septum pellucidum +/- pituitary hormone deficiency
-Cleft lip palate -Single upper central incisor syndrome
![Page 35: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/35.jpg)
Fizik Muayene-1:
• TY: 11 yaş 11 ay iken• Boy: 131 cm• Boy SDS: - 3.4• VA: 28 kg• BMI: 16,32 kg/m²• KY: 11-12 YAŞ
![Page 36: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/36.jpg)
Radyoloji:
![Page 37: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/37.jpg)
![Page 38: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/38.jpg)
BH gene defects
• All patients with classical GH gene deletions have complete GHD(IGHD IA, IB,2,3(+hypogammaglobulinemic))
![Page 39: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/39.jpg)
GH gene regulation:• Pit1 (pituitary transcription
factor):stimulatory effect on GH gene transcription
• Pit 1 mutations - Severe deficiencies in GH PRI- Often develop secondary hypothyrodism• Prop 1 (Prophet of pit 1) mutations
combined pituitary hormone deficiency(secondary hypogonadism)
![Page 40: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/40.jpg)
![Page 41: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/41.jpg)
Davis 2010
![Page 42: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/42.jpg)
Clinical features of GHD• Growth failure• Normal birth weight and birth length• Skeletal proportions normal for age• Somewhat overweight for height(increased subcutaneous fat)• Head circumference normal• Disparity between the size of face and the calvarium: “doll like”
“cherubic” facies most pronounced in panhypopituitarism (crowding of the facial features to the centre of the face suggesting maxillary hypoplasia)- frontal bossing, saddle nose
• Skeletal maturity delayed• High pitched voice• Males: penis,scrotum small, hypoplastic testis• Hypoglycemia
![Page 43: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/43.jpg)
![Page 44: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/44.jpg)
![Page 45: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/45.jpg)
![Page 46: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/46.jpg)
• Radiological assessment: Skull x rays,CT, MRI
• IGF 1 measurement, physiological tests of GH secretion
![Page 47: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/47.jpg)
O.E
![Page 48: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/48.jpg)
G.Ö
![Page 49: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/49.jpg)
B.Y
![Page 50: Growth Disorders](https://reader036.vdocuments.site/reader036/viewer/2022062812/568163f6550346895dd585d5/html5/thumbnails/50.jpg)
M.Ş